Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

MT Newswires Live06-11

Humacyte (HUMA) said Wednesday that its bioengineered blood vessel, the acellular tissue engineered vessel, or ATEV, met the primary endpoint in a late-stage study of female patients requiring dialysis access.

In the interim analysis of the study, the first 80 patients who received ATEV had an average of 91 more catheter-free days than patients who received the current standard of care, an autologous arteriovenous fistula, according to a statement.

The company said it plans to file a supplemental biologic license application with the US Food and Drug Administration in the second half of the year.

The biotechnology company has also launched a public offering of common stock to fund the commercialization of Symvess, the filing of a Biologics License Application supplement for a hemodialysis indication, and the development of product candidates in its pipeline.

Underwriters are expected to have a 30-day option to buy up to an additional 15% of the shares offered, it said.

Shares of the company fell over 11% in after-hours trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642476244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 04:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642476244","market":"us","top_or_hot":-1,"title":"Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall","media":"MT Newswires Live","content":"<html><body><p> Humacyte (HUMA) said Wednesday that its bioengineered blood vessel, the acellular tissue engineered vessel, or ATEV, met the primary endpoint in a late-stage study of female patients requiring dialysis access.</p><p>In the interim analysis of the study, the first 80 patients who received ATEV had an average of 91 more catheter-free days than patients who received the current standard of care, an autologous arteriovenous fistula, according to a statement.</p><p>The company said it plans to file a supplemental biologic license application with the US Food and Drug Administration in the second half of the year.</p><p>The biotechnology company has also launched a public offering of common stock to fund the commercialization of Symvess, the filing of a Biologics License Application supplement for a hemodialysis indication, and the development of product candidates in its pipeline.</p><p>Underwriters are expected to have a 30-day option to buy up to an additional 15% of the shares offered, it said.</p><p>Shares of the company fell over 11% in after-hours trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-11 04:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Humacyte (HUMA) said Wednesday that its bioengineered blood vessel, the acellular tissue engineered vessel, or ATEV, met the primary endpoint in a late-stage study of female patients requiring dialysis access.</p><p>In the interim analysis of the study, the first 80 patients who received ATEV had an average of 91 more catheter-free days than patients who received the current standard of care, an autologous arteriovenous fistula, according to a statement.</p><p>The company said it plans to file a supplemental biologic license application with the US Food and Drug Administration in the second half of the year.</p><p>The biotechnology company has also launched a public offering of common stock to fund the commercialization of Symvess, the filing of a Biologics License Application supplement for a hemodialysis indication, and the development of product candidates in its pipeline.</p><p>Underwriters are expected to have a 30-day option to buy up to an additional 15% of the shares offered, it said.</p><p>Shares of the company fell over 11% in after-hours trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642476244","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642476244","pubTimestamp":1781124672,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Humacyte (HUMA) said Wednesday that its bioengineered blood vessel, the acellular tissue engineered vessel, or ATEV, met the primary endpoint in a late-stage study of female patients requiring dialysi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HUMA":"Humacyte, Inc.","BK4563":"昨日强势股"},"translate_title":"Humacyte表示ATEV在中期分析中达到了后期研究终点，启动公开发行；股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":1},"content_text":"Humacyte (HUMA) said Wednesday that its bioengineered blood vessel, the acellular tissue engineered vessel, or ATEV, met the primary endpoint in a late-stage study of female patients requiring dialysis access.In the interim analysis of the study, the first 80 patients who received ATEV had an average of 91 more catheter-free days than patients who received the current standard of care, an autologous arteriovenous fistula, according to a statement.The company said it plans to file a supplemental biologic license application with the US Food and Drug Administration in the second half of the year.The biotechnology company has also launched a public offering of common stock to fund the commercialization of Symvess, the filing of a Biologics License Application supplement for a hemodialysis indication, and the development of product candidates in its pipeline.Underwriters are expected to have a 30-day option to buy up to an additional 15% of the shares offered, it said.Shares of the company fell over 11% in after-hours trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642476244","isCrawlerRequest":true}